DE69907870D1 - Verfahren zur herstellung von absorbierbaren mikropartikeln - Google Patents

Verfahren zur herstellung von absorbierbaren mikropartikeln

Info

Publication number
DE69907870D1
DE69907870D1 DE69907870T DE69907870T DE69907870D1 DE 69907870 D1 DE69907870 D1 DE 69907870D1 DE 69907870 T DE69907870 T DE 69907870T DE 69907870 T DE69907870 T DE 69907870T DE 69907870 D1 DE69907870 D1 DE 69907870D1
Authority
DE
Germany
Prior art keywords
microparticles
producing
producing absorbable
absorbable microparticles
absorbable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69907870T
Other languages
English (en)
Other versions
DE69907870T2 (de
Inventor
Thomas Ciaran Loughman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Manufacturing Ireland Ltd
Original Assignee
Kinerton Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Ltd filed Critical Kinerton Ltd
Application granted granted Critical
Publication of DE69907870D1 publication Critical patent/DE69907870D1/de
Publication of DE69907870T2 publication Critical patent/DE69907870T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide
DE69907870T 1998-01-29 1999-01-25 Verfahren zur herstellung von absorbierbaren mikropartikeln Expired - Lifetime DE69907870T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE980054 1998-01-29
IE980054 1998-01-29
PCT/IE1999/000007 WO1999038535A1 (en) 1998-01-29 1999-01-25 Process for making absorbable microparticles

Publications (2)

Publication Number Publication Date
DE69907870D1 true DE69907870D1 (de) 2003-06-18
DE69907870T2 DE69907870T2 (de) 2004-03-04

Family

ID=11041696

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69907870T Expired - Lifetime DE69907870T2 (de) 1998-01-29 1999-01-25 Verfahren zur herstellung von absorbierbaren mikropartikeln

Country Status (17)

Country Link
US (1) US6555156B1 (de)
EP (1) EP1051194B9 (de)
JP (1) JP2002501907A (de)
CN (1) CN1289255A (de)
AR (1) AR014069A1 (de)
AT (1) ATE240121T1 (de)
AU (1) AU740493B2 (de)
CA (1) CA2318513A1 (de)
DE (1) DE69907870T2 (de)
DK (1) DK1051194T3 (de)
ES (1) ES2194437T3 (de)
HU (1) HUP0102373A2 (de)
IL (1) IL137349A0 (de)
NO (1) NO20003804L (de)
PL (1) PL342135A1 (de)
PT (1) PT1051194E (de)
WO (1) WO1999038535A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
IES990700A2 (en) * 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
EA008829B1 (ru) 2002-12-17 2007-08-31 Нэстек Фармасьютикал Кампани Инк. Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
WO2005070444A2 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
CA2552677A1 (en) * 2004-01-13 2005-07-28 Vasogenix Pharmaceuticals, Inc. Controlled release cgrp delivery composition for cardiovascular and renal indications
WO2005070445A2 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
US7578951B2 (en) * 2004-01-27 2009-08-25 Hewlett-Packard Development Company, L.P. Method of making microcapsules utilizing a fluid ejector
US20060084628A1 (en) 2004-10-19 2006-04-20 Achillion Pharmaceuticals Combination therapy for treating viral infections
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN101730708B (zh) 2007-03-28 2013-09-18 哈佛大学校长及研究员协会 缝合多肽
EP2315571A4 (de) * 2008-07-16 2013-05-01 Surmodics Pharmaceuticals Inc Verfahren zur herstellung von mikropartikeln mit bioaktiven peptiden
US8968787B2 (en) * 2010-05-24 2015-03-03 Micro Powders, Inc. Composition comprising biodegradable polymers for use in a cosmetic composition
CA2807685C (en) 2010-08-13 2020-10-06 Aileron Therapeutics, Inc. P53 derived peptidomimetic macrocycle
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス,インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
BR112017019738A2 (pt) 2015-03-20 2018-05-29 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
US10953103B2 (en) 2015-11-06 2021-03-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V Composition comprising a biocompatible and biodegradable polymer, nanocarriers and a drug and methods of making and using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
JPH07503700A (ja) * 1991-01-03 1995-04-20 アルカーメス コントロールド セラピューティックス, インコーポレイテッド カチオン生体ポリマーによるタンパク質の安定化
US5366756A (en) 1992-06-15 1994-11-22 United States Surgical Corporation Method for treating bioabsorbable implant material
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
CA2167920A1 (en) * 1993-07-23 1995-02-02 Abraham J. Domb Nonoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US6270700B1 (en) * 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides

Also Published As

Publication number Publication date
AU740493B2 (en) 2001-11-08
CN1289255A (zh) 2001-03-28
IL137349A0 (en) 2001-07-24
EP1051194B9 (de) 2003-11-05
WO1999038535A1 (en) 1999-08-05
PT1051194E (pt) 2003-09-30
PL342135A1 (en) 2001-05-21
HUP0102373A2 (hu) 2001-10-28
ATE240121T1 (de) 2003-05-15
DE69907870T2 (de) 2004-03-04
NO20003804L (no) 2000-09-20
ES2194437T3 (es) 2003-11-16
AR014069A1 (es) 2001-01-31
AU2296699A (en) 1999-08-16
JP2002501907A (ja) 2002-01-22
EP1051194B1 (de) 2003-05-14
EP1051194A1 (de) 2000-11-15
US6555156B1 (en) 2003-04-29
NO20003804D0 (no) 2000-07-25
DK1051194T3 (da) 2003-09-01
CA2318513A1 (en) 1999-08-05

Similar Documents

Publication Publication Date Title
DE69907870D1 (de) Verfahren zur herstellung von absorbierbaren mikropartikeln
ATE297892T1 (de) Verfahren zur herstellung von azetidinonen
DE60005779D1 (de) Verfahren zur herstellung von polyarylaten
DE69911398D1 (de) Verfahren zur herstellung von 4-aminodiphenylaminen
DE69913666D1 (de) Verfahren zur herstellung von di-methyl-naphthalinen
ATE339433T1 (de) Verbessertes verfahren zur herstellung von makroliden
DE60003264D1 (de) Verfahren zur herstellung von glycerylethern
DE50004356D1 (de) Verfahren zur herstellung von adrenalin
DE59901552D1 (de) Verfahren zur herstellung von polyalkylenarylaten
DE69914469D1 (de) Verfahren zur herstellung von hinokitiol
DE50006772D1 (de) Verfahren zur herstellung von oxindolen
ATE274511T1 (de) Verfahren zur herstellung von eprosartan
DE69910995D1 (de) Verfahren zur herstellung von fluorkohlenwasserstoffen
DE69827240D1 (de) Verfahren zur herstellung von eprosartan
DE50001895D1 (de) Verfahren zur herstellung von phosphonomethylglycin
ATE233238T1 (de) Verfahren zur herstellung von 3-acyl-indolen
DE69902190T2 (de) Verfahren zur herstellung von polyester
ATE272611T1 (de) Verfahren zur herstellung von ketiminen
DE69928784D1 (de) Verfahren zur herstellung von oxazolidin-2-on-derivaten
DE69901192T2 (de) Verfahren zur herstellung von cyclopropanmethylamin
DE59903764D1 (de) Verfahren zur herstellung von phytosqualan
DE69910353D1 (de) Verfahren zur herstellung von epsilon-caprolactam
DE59907204D1 (de) Verfahren zur herstellung von cyclopentanon
DE69920762D1 (de) Verfahren zur herstellung von polysuccinimiden
ATE207901T1 (de) Verfahren zur herstellung von 2-chlor-3- hydroxypyridin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: IPSEN MANUFACTURING IRELAND LTD., DUBLIN, IE